Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2015

View Archived Issues

Regeneron designs human antibodies to PD-1

New MoA: Novel ATAD2 bromodomain inhibitors

Thomas Jefferson University and University of Pennsylvania present fusion proteins

FDA grants orphan drug designation to MTG-201 for mesothelioma

Medivation to acquire all worldwide rights to talazoparib from BioMarin

IDMC recommends reduction of cardiac toxicity monitoring in PRESENT trial

FDA accepts IND application for tazemetostat in INI1-negative tumors or synovial sarcoma

RetroSense Therapeutics' RST-001 obtains FDA clearance to proceed to first-in-human trials

Jacobus Pharmaceutical reports development of novel antimalarials

Unsolicited offer to acquire InSite Vision deemed as better than QLT's proposal

Clinical trial results detailed for tofacitinib in psoriasis

Daiichi Sankyo announces Japanese approvals for supplementary indications

Esperance and MD Anderson Cancer Center form EP-100 alliance

Researchers confirm brain-selectivity of estrogen prodrug, potential for menopause disorders

FDA awards breakthrough therapy designation to cabozantinib for RCC

FDA approves Promacta for young children with chronic ITP

Remicade approved in Japan for entero-Behcet's, neuro-Behcet's and vasculo-Behcet's disease

Roche acquires nucleic acid purification assets from Lumora

TxCell receives French government grant to fund Col-Treg development

Filings accepted for afatinib as second-line treatment for squamous cell carcinoma of the lung

Pfizer conducting first-in-human study of PF-06751979

Cristal Therapeutics initiates phase I study of CriPec docetaxel for solid tumors

Lundbeck announces progress of second quarter 2015 and restructuring

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026